



# Dr. med. Michael Montemurro

FMH Specialist in Hematology

FMH Specialist in Internal Medicine

Specialist in Internal Medicine, Hematology and Medical Oncology

---

## Languages

EN,DE,FR,IT

## Work Experience

since 2021	Consultant, Medical Oncology - University College London Hospitals, UK
2020	Chief Physician, Medical Oncology - EHC Morges Hospital, CH
2016-2020	Deputy Physician, Medical Oncology - CHUV Lausanne, CH
2014-2015	Associate Physician, Medical Oncology - IOSI-EOC, Ospedale Bellinzona, CH
2013-2014	Sarcoma Unit, The Royal Marsden Hospital London, UK
2012	Medical oncology, CHU Zurich, CH
2005-2012	Multidisciplinary Oncology Center (CePO), CHUV Lausanne, CH

## Education

2019	ESMO Exam Medical Oncology
2003	Internal hematology and oncology
2002	Internal Medicine
1999	Research thesis, Faculty of Medicine, Essen University, Germany
1989-1995	Medical studies, Johann Wolfgang Goethe Universität, Frankfurt, Germany

## Competences

- Digestive tumors: colon, rectum, liver, pancreas, stomach, esophagus, neuro-endocrine
- GIST (gastrointestinal stromal tumor)
- Soft tissue and bone sarcomas

## Memberships

- 2009 - 2020: ESMO Faculty Member GIST / Sarcoma (ESMO Guidelines Sarcoma, GIST)
- 2011 - 2016: President of SAKK project group "Gastrointestinal Cancer"
- 2010: Founding member of "Groupe GIST Suisse"

## Publications

- Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma  
Montemurro M, 2021 Feb;27(2):289-300
- Prediction of tumor grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma. Dunet V, Halkic N, Sempoux C, Demartines N, Montemurro M, Prior JO, Schmidt S.; Eur Radiol. 2021 Feb;31(2):992-1001
- LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma  
Montemurro, M., et al. Cell Rep. 2020 Mar 31;30(13):4567-4583
- Oncological outcome, functional results and costs after unplanned excision of musculoskeletal soft tissue sarcoma  
Morattel , Mustaki, Montemurro, Letovanec, Durham, Becce, Omoumi, di Summa, Matter, Rüdiger , Cherix Eur J Surg Oncol. 2020 May;46(5):898-904
- Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis ....  
Du Pasquier C, Roulin D, Bize P, Sempoux C, Rebecchini C, Montemurro M, Schaffner M, Halkic N, Demartines N. BMC Surg. 2020 Apr 19;20(1):78
- Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer...  
De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Zeverino M, Ozsahin M. J Cancer Res Clin Oncol. 2019 Apr;145(4):1075-1084
- Long-term outcome of dasatinib first-line treatment in GIST: A multicenter, 2-stage phase 2 trial (SAKK 56/07).  
Montemurro M et al.; Cancer. 2018 Apr 1;124(7):1449-1454
- Sarcoma of the heart: survival after surgery.  
Niclauss L, Montemurro M, Kirsch M, Preître R.; Interact Cardiovasc Thorac Surg. 2018 Aug; 27(2):198-201
- Radiation Therapy for GIST Progressing During Or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study  
Joensuu H, Eriksson M, Collan J, Balk M, Leyvraz S, Montemurro M; Radiother Oncol. 2015 Aug; 116(2):233-8
- Survival after surgical drainage of malignant pericardial effusion Niclauss L, Montemurro M, Preître R; World J Surg 2015 Jul;39(7):1767
- Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour .....  
M. Montemurro et al.; European Journal of Cancer 2013 Mar;49(5):1027-31
- Continuous Sunitinib treatment in patients with advanced HCC: a SAKK and SASL multicenter phase II trial (SAKK 77/06). Koeberle D, Montemurro M et al.; Oncologist. 2010;15(3):285-92.
- Early prediction of response to sunitinib after imatinib failure by 18F-FDG-PET in patients with GIST  
Prior JO, Montemurro M et al.; J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8. Nilotinib in the treatment of advanced gastrointestinal stromal tumors resistant to both imatinib and sunitinib. Montemurro M et al.; Eur J Cancer. 2009 Sep;45(13):2293-7
- PCNSL treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II study. Montemurro M et al.; Ann Oncol. 2007 Apr;18(4):665-71.
- Book chapter**  
Principles of Tumor Therapy  
In: "HEROLD - INNERE MEDIZIN", Gerd Herold (editor), Germany; since 2010, annual update

## Awards

- 2018 : Annual prize of GIST Group / Swiss Group
- 2012 : Annual prize of GIST Group / Swiss Group
- 2011 : Honorary Prize of the GIST Group Switzerland for "Living with GIST"

- 2011 : Edi 2011 (silver): Film documentary: "Living with GIST"
- 2011 : Honorary member of GIST Group Switzerland (www.gist.ch)
- 2010 : Annual prize of GIST Group / Swiss Group

## Accreditation

[Clinique de Genolier](#)

[Clinique de Montchoisi](#)

## Specialties

[Hematology](#)

[General Internal Medicine](#)

[Oncology](#)

[Onco-haematology](#)

## Contact

**Clinique de Genolier**

Route du Muids 3

1272 Genolier

T T +41 22 366 90 72

[fmansouri@genolier.net](mailto:fmansouri@genolier.net)

[Download vCard](#)